Clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers.

Clinical-stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects

Clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization.

Clinical-stage biopharmaceutical company leveraging a proprietary microRNA-based target discovery platform to develop first-in-class small molecule and antibody cancer therapeutics.

Clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases.

Clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics called engineered toxin bodies (ETBs).

Clinical-stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies for cancer.

Clinical stage biotechnology company developing therapeutics targeting stress support pathways.

Clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment.

Dedicated to creating life-changing T Cell therapies for patients by unleashing the untapped potential of the human immune system.

Commercial-stage biopharmaceutical company developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology.